Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis

Antonio Ahumada-Canale, Constanza Vargas, Carlos Balmaceda, Francisco Martinez-Mardones, José Cristian Plaza-Plaza, Shalom Benrimoj, Victoria Garcia-Cardenas

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Aim: To assess the trial-based cost–effectiveness of medication review with follow-up comparedwith usual care in primary care.

Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost– effectiveness ratio.

Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03).
Conclusion: The intervention was cost-effective in the public primary care setting.
Original languageEnglish
Pages (from-to)229-242
Number of pages14
JournalJournal of Comparative Effectiveness Research
Issue number3
Publication statusPublished - Feb 2021


  • aged
  • cardiovascular system
  • cost–effectiveness
  • drug monitoring
  • economics
  • pharmacy


Dive into the research topics of 'Medication review with follow-up for cardiovascular outcomes: a trial based cost–utility analysis'. Together they form a unique fingerprint.

Cite this